Literature DB >> 21907694

Protease activated receptor-2 mediates activated protein C-induced cutaneous wound healing via inhibition of p38.

Sohel M Julovi1, Meilang Xue, Suat Dervish, Philip N Sambrook, Lyn March, Christopher John Jackson.   

Abstract

Activated protein C (APC) is a natural anticoagulant that exerts anti-inflammatory and cytoprotective properties mediated through the protease activated receptor (PAR)-1. APC can also proteolytically cleave PAR-2, although subsequent function is unknown. On the basis of recent evidence that APC promotes wound healing, the aim of this study was to determine whether APC acts through PARs to heal murine excisional wounds or to regulate human cultured keratinocyte function and to determine the signaling mechanisms. Topical administration of APC accelerated wound healing in wild-type mice and, unexpectedly, in PAR-1 knockout mice. PAR-2 knockout mice healed significantly slower than wild-type mice, and healing was not altered by adding APC, indicating that APC acts through PAR-2 to heal wounds. In cultured human primary keratinocytes, APC enhanced PAR-2, stimulated proliferation, activated phosphatidylinositol 3-kinase/Src/Akt, and inhibited phosphorylated (P)-p38. Inhibiting PAR-1 or PAR-2, by small-interfering RNA or blocking antibody, reversed APC-induced keratinocyte proliferation and Akt activation. Blocking PAR-2, but not PAR-1, reversed the inhibition of P-p38 by APC. Furthermore, inhibition of P-p38 accelerated wound healing in wild-type mice. In summary, although APC acts through both PAR-1 and PAR-2 to activate Akt and to increase keratinocyte proliferation, APC-induced murine wound healing depends on PAR-2 activity and inhibition of P-p38.
Copyright © 2011 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21907694      PMCID: PMC3204081          DOI: 10.1016/j.ajpath.2011.07.024

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  53 in total

1.  Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism.

Authors:  M Steinhoff; N Vergnolle; S H Young; M Tognetto; S Amadesi; H S Ennes; M Trevisani; M D Hollenberg; J L Wallace; G H Caughey; S E Mitchell; L M Williams; P Geppetti; E A Mayer; N W Bunnett
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

2.  MAPK p38 antagonism as a novel method of inhibiting lymphoid immune suppression in polymicrobial sepsis.

Authors:  G Y Song; C S Chung; I H Chaudry; A Ayala
Journal:  Am J Physiol Cell Physiol       Date:  2001-08       Impact factor: 4.249

3.  Proteinase-activated receptor 2 is an anti-inflammatory signal for colonic lamina propria lymphocytes in a mouse model of colitis.

Authors:  S Fiorucci; A Mencarelli; B Palazzetti; E Distrutti; N Vergnolle; M D Hollenberg; J L Wallace; A Morelli; G Cirino
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

4.  Efficacy and safety of recombinant human activated protein C for severe sepsis.

Authors:  G R Bernard; J L Vincent; P F Laterre; S P LaRosa; J F Dhainaut; A Lopez-Rodriguez; J S Steingrub; G E Garber; J D Helterbrand; E W Ely; C J Fisher
Journal:  N Engl J Med       Date:  2001-03-08       Impact factor: 91.245

5.  Protease-activated receptor-2 modulates myocardial ischemia-reperfusion injury in the rat heart.

Authors:  C Napoli; C Cicala; J L Wallace; F de Nigris; V Santagada; G Caliendo; F Franconi; L J Ignarro; G Cirino
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

6.  Intratracheal administration of activated protein C inhibits bleomycin-induced lung fibrosis in the mouse.

Authors:  H Yasui; E C Gabazza; S Tamaki; T Kobayashi; O Hataji; H Yuda; S Shimizu; K Suzuki; Y Adachi; O Taguchi
Journal:  Am J Respir Crit Care Med       Date:  2001-06       Impact factor: 21.405

7.  Activated protein C enhances human keratinocyte barrier integrity via sequential activation of epidermal growth factor receptor and Tie2.

Authors:  Meilang Xue; Shu-Oi Chow; Suat Dervish; Yee-Ka Agnes Chan; Sohel M Julovi; Christopher J Jackson
Journal:  J Biol Chem       Date:  2010-12-20       Impact factor: 5.157

8.  The protease-activated receptor-2 agonist induces gastric mucus secretion and mucosal cytoprotection.

Authors:  A Kawabata; M Kinoshita; H Nishikawa; R Kuroda; M Nishida; H Araki; N Arizono; Y Oda; K Kakehi
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

9.  Thrombin responses in human endothelial cells. Contributions from receptors other than PAR1 include the transactivation of PAR2 by thrombin-cleaved PAR1.

Authors:  P J O'Brien; N Prevost; M Molino; M K Hollinger; M J Woolkalis; D S Woulfe; L F Brass
Journal:  J Biol Chem       Date:  2000-05-05       Impact factor: 5.157

10.  Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia.

Authors:  Judith Branger; Bernt van den Blink; Sebastiaan Weijer; Jeffrey Madwed; Carina L Bos; Abhya Gupta; Chan-Loi Yong; Stephen H Polmar; Dariusz P Olszyna; C Erik Hack; Sander J H van Deventer; Maikel P Peppelenbosch; Tom van der Poll
Journal:  J Immunol       Date:  2002-04-15       Impact factor: 5.422

View more
  13 in total

1.  Hepatocyte growth factor activator inhibitor type 1 maintains the assembly of keratin into desmosomes in keratinocytes by regulating protease-activated receptor 2-dependent p38 signaling.

Authors:  Makiko Kawaguchi; Ai Kanemaru; Akira Sawaguchi; Koji Yamamoto; Takashi Baba; Chen-Yong Lin; Michael D Johnson; Tsuyoshi Fukushima; Hiroaki Kataoka
Journal:  Am J Pathol       Date:  2015-04-01       Impact factor: 4.307

Review 2.  Extracellular Matrix Reorganization During Wound Healing and Its Impact on Abnormal Scarring.

Authors:  Meilang Xue; Christopher J Jackson
Journal:  Adv Wound Care (New Rochelle)       Date:  2015-03-01       Impact factor: 4.730

Review 3.  Mechanisms of anticoagulant and cytoprotective actions of the protein C pathway.

Authors:  E A M Bouwens; F Stavenuiter; L O Mosnier
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824

4.  [Treatment failure after postinfectious purpura fulminans despite interdisciplinary surgical and intensive medical therapy].

Authors:  S A Alawi; R Ipaktchi; K Suchodolski; A Jokuszies
Journal:  Med Klin Intensivmed Notfmed       Date:  2020-02-13       Impact factor: 0.840

5.  Activated protein C to heal pressure ulcers.

Authors:  Aruna Wijewardena; Sepehr S Lajevardi; Elle Vandervord; John Vandervord; Thomas C Lang; Gregory Fulcher; Christopher J Jackson
Journal:  Int Wound J       Date:  2014-09-03       Impact factor: 3.315

Review 6.  Activated protein C: A regulator of human skin epidermal keratinocyte function.

Authors:  Kelly McKelvey; Christopher John Jackson; Meilang Xue
Journal:  World J Biol Chem       Date:  2014-05-26

Review 7.  Contribution of platelets, the coagulation and fibrinolytic systems to cutaneous wound healing.

Authors:  Aman Opneja; Sargam Kapoor; Evi X Stavrou
Journal:  Thromb Res       Date:  2019-05-02       Impact factor: 3.944

8.  Abnormal joint and bone wound healing in hemophilia mice is improved by extending factor IX activity after hemarthrosis.

Authors:  Junjiang Sun; Baolai Hua; Eric W Livingston; Sarah Taves; Peter B Johansen; Maureane Hoffman; Mirella Ezban; Dougald M Monroe; Ted A Bateman; Paul E Monahan
Journal:  Blood       Date:  2016-12-30       Impact factor: 22.113

9.  Activated protein C inhibits proliferation and tumor necrosis factor α-stimulated activation of p38, c-Jun NH2-terminal kinase (JNK) and Akt in rheumatoid synovial fibroblasts.

Authors:  Sohel M Julovi; Kaitlin Shen; Kelly Mckelvey; Nikita Minhas; Lyn March; Christopher J Jackson
Journal:  Mol Med       Date:  2013-10-24       Impact factor: 6.354

10.  Treatment of chronic diabetic lower leg ulcers with activated protein C: a randomised placebo-controlled, double-blind pilot clinical trial.

Authors:  Kaley Whitmont; Kelly J McKelvey; Gregory Fulcher; Ian Reid; Lyn March; Meilang Xue; Alan Cooper; Christopher J Jackson
Journal:  Int Wound J       Date:  2013-07-15       Impact factor: 3.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.